Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer

Pancreatic cancer is the fifth leading cause in cancer related death among adults in the United States. Thirty-thousand new cases of pancreatic cancer are diagnosed each year, most are metastatic at diagnosis and no effective systemic therapy is available. 773U82 mesylate is one of a series of compo...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1994-01, Vol.12 (4), p.273-276
Main Authors: TRUMP, D. L, HATHORN, J. A, GROCHOW, L. B, SPRIGGS, D, EBLE, M. L, HOHNEKER, J. A
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma - drug therapy
Chemotherapy
Female
Fluorenes - adverse effects
Fluorenes - therapeutic use
Humans
Male
Medical sciences
Middle Aged
Pancreatic Neoplasms - drug therapy
Pharmacology. Drug treatments
Propylene Glycols - adverse effects
Propylene Glycols - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is the fifth leading cause in cancer related death among adults in the United States. Thirty-thousand new cases of pancreatic cancer are diagnosed each year, most are metastatic at diagnosis and no effective systemic therapy is available. 773U82 mesylate is one of a series of compounds (arylmethylaminopropanediols-AMAPS) which was synthesized at the Wellcome Research Laboratories. AMAPS bind to DNA, show evidence of topoisomerase 2 inhibition and are active in a variety of murine and human preclinical screens. Based on these data a phase II trial of 773U82 mesylate administered at 800 mg/m2 daily x 3 at a 4 h infusion repeated every three weeks was carried out. Patients eligible for these trials had histologic proof of adenocarcinoma, good performance status, and normal organ function. This was a multi-institutional trial. Nineteen patients were entered; 15 patients were fully eligible and 4 were ineligible, but were evaluated. Thirteen patients were fully evaluable for response and no response was seen. Median time to progressive disease among eligible patients was 56 days. Toxicity of 773U82 mesylate was myelosuppression which was not prohibitive. 773U82 mesylate is not active in pancreatic cancer.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00873040